The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group

Eur J Haematol. 2001 Jan;66(1):57-62. doi: 10.1034/j.1600-0609.2001.00338.x.

Abstract

Objectives: To investigate the relationship between an insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor (PAI)-1 gene and childhood patients with a past history of ischemic stroke.

Methods: The PAI-1 4G/4G genotype and the coinheritance with lipoprotein (Lp) (a) levels, the factor V (FV) G1691A mutation, the prothrombin (PT) G20210A variant, and the methylene-tetrahydrofolate reductase (MTHFR) T677T genotype were studied in 198 Caucasian children with stroke and 951 controls (same age, sex and ethnical distribution). In a randomly selected subgroup of patients/controls (n=60) PAI-I activities have been investigated.

Results: The distribution of the 4G/5G genotypes was no different in childhood stroke patients and controls, with a 4G allele frequency of 55.8% in patients compared with 53.8% in control subjects (P=0.49). The 4G/4G genotype compared with the remaining genotypes was present in 43 cases and 167 (17.6% vs. 21.7%; OR/CI: 1.30/0.89-1.98; P=0.3). PAI-1 activity was significantly elevated (P < 0.001) in the patient group.

Conclusions: Data presented here suggest that the 4G/4G genotype is not a major risk factor in the aetiology of childhood ischemic stroke.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions / genetics
  • Activated Protein C Resistance / epidemiology
  • Activated Protein C Resistance / genetics
  • Adolescent
  • Age of Onset
  • Brain Ischemia / epidemiology
  • Brain Ischemia / genetics*
  • Child
  • Child, Preschool
  • Factor V / analysis
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Germany / epidemiology
  • Humans
  • Infant
  • Lipoprotein(a) / analysis
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Mutagenesis, Insertional
  • Oxidoreductases Acting on CH-NH Group Donors / genetics
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Point Mutation
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic / genetics*
  • Prospective Studies
  • Prothrombin / genetics
  • Risk Factors
  • Sequence Deletion
  • Thrombophilia / complications
  • Thrombophilia / genetics*
  • White People / genetics

Substances

  • 3' Untranslated Regions
  • Lipoprotein(a)
  • Plasminogen Activator Inhibitor 1
  • factor V Leiden
  • Factor V
  • Prothrombin
  • Oxidoreductases Acting on CH-NH Group Donors
  • Methylenetetrahydrofolate Reductase (NADPH2)